Preclinical Research Study
We provide accelerated development and competitive advantage across multiple therapeutic areas through successful GLP studies. Our specialized preclinical CRO/CDMO team has rich experience and state-of-the-art facilities to identify the most promising compounds for your drugs and biology needs.
At Jubilant Biosys, we are committed to meeting the client’s needs while maintaining the quality and integrity of the project outsourced to us. Our in-house team consistently deliver high-quality results for narrowing the selection of drug candidates in preclinical and early drug development process.

Target to Lead Generation
Our target identification process is designed to meet the specific needs of our clients using high-throughput screening, helping them make key decisions about their lead candidate.
- Structural Biology (Protein Science, Crystallography)
- Medicinal and Computational Chemistry
- Screening & Profiling
- Early ADMET & PK
- In vitro / In vivo Pharmacology
Lead Optimization
Turn on to our lead optimization solutions. With an experienced cross-functional team, we help our partners fulfil their preclinical research needs and accelerate their timeline to reach the clinical phase rapidly.
- Medicinal Chemistry
- DMPK
- SBDD (Co-crystallization, Computational Modelling)
- Target Engagement & Disease Models
- Safety Profile
- Pre-formulation
Candidate Selection (IND)
From lead to candidate selection, we help our partners determine their best candidate through careful assessment of toxicology and efficacy before entering human trials.
- Process Development
- Scale-up & GMP API Supply
- Genotox
- Non-GLP & GLP Tox
- D2M Predictions (WinNonlin)